We demonstrate that efficacy of TKI therapy in FLT3-mutated AML is highly dependent on the mutational landscape within each leukemia and provide a valuable framework for designing rational combination therapy in FLT3-ITD AML. Here, FLT3 is linked to acute myeloid leukemia.